title: Targeted drug delivery system for oral cancer therapy using sonoporation.
abstract: Ultrasound-mediated destruction of microbubbles has been proposed as an innovative non-invasive drug delivery system for cancer therapy. We developed a specific drug delivery system for squamous cell carcinoma that uses sonoporation with the anti-epidermal growth factor receptor (EGFR) antibody. Administration of a low dose of bleomycin (BLM) by sonoporation with the anti-EGFR antibody produced a marked growth inhibition of Ca9-22 cells in vitro. In addition, scanning electron microscopic analysis revealed apparent surface deformation of Ca9-22 cells treated with sonoporation in the presence of the antibody. Interestingly, the population of apoptotic cells was remarkably increased when a low dose of BLM was delivered using sonoporation with the Fab fragment of the anti-EGFR antibody. These findings indicate that sonoporation with the Fab fragment makes it possible to administer drugs into cells more efficiently and specifically, suggesting a novel application for chemotherapy and gene therapy treatments for oral squamous cell carcinoma.
authors: Division of Infection and Molecular Biology, Department of Health Promotion, Kyushu Dental College, Kitakyushu, Japan.
authors: Hironobu
authors: H
authors: Maeda
authors: Kazuhiro
authors: K
authors: Tominaga
authors: Kenjiro
authors: K
authors: Iwanaga
authors: Fuminori
authors: F
authors: Nagao
authors: Manabu
authors: M
authors: Habu
authors: Toshiyuki
authors: T
authors: Tsujisawa
authors: Yuji
authors: Y
authors: Seta
authors: Kuniaki
authors: K
authors: Toyoshima
authors: Jin-ichi
authors: J
authors: Fukuda
authors: Tatsuji
authors: T
authors: Nishihara
mesh_terms: D000906:Antibodies / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems / Q000379:methods*; D066246:ErbB Receptors / Q000276:immunology; D005887:Gingival Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000276:immunology; D000922:Immunotoxins / Q000008:administration & dosage*; D045423:Microbubbles; D014407:Tumor Cells, Cultured; D014465:Ultrasonics
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D007140:Immunoglobulin Fab Fragments; D000922:Immunotoxins; D001761:Bleomycin; D066246:ErbB Receptors